Abstract
Introduction
Innate immunity provides a first line of host defense against infection by recognizing and killing microbes while simultaneously activating an instructive immune response. Toll-like receptors (TLRs) are principal mediators of rapid microbial recognition and function mainly by detection of pathogen-associated molecular patterns that do not exist in the host. Recognition of their ligands leads to a series of signaling events resulting in acute host responses, involved in killing pathogens.
Discussion
We describe the involvement of TLR4 polymorphisms in ageing, and in particular in age-related diseases, suggesting the crucial role of molecules of innate immunity in pathophysiology of these diseases. Hence, we observed that pro-inflammatory alleles may be related to unsuccessful ageing, such as Alzheimer’s disease, prostate cancer, and atherosclerosis; in contrast, the control of inflammation by anti-inflammatory alleles may result in increased longevity and successful ageing. Finally, a possible therapeutic approach to delay age-related diseases is outlined.
Similar content being viewed by others
References
De Benedictis G, Franceschi C. The unusual genetics of human longevity. Sci Aging Knowledge Environ. 2006;2006(10):pe20. doi:10.1126/sageke.2006.10.pe20.
Salvioli S, Olivieri F, Marchegiani F, Cardelli M, Santoro A, Bellavista E, et al. Genes, ageing and longevity in humans: problems, advantages and perspectives. Free Radic Res. 2006;40:1303–23. doi:10.1080/10715760600917136.
Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation. 2008;15:224–40. doi:10.1159/000156466.
Candore G, Balistreri CR, Listì F, Grimaldi MP, Vasto S, Colonna-Romano G, et al. Immunogenetics, gender, and longevity. Ann N Y Acad Sci. 2006;1089:516–37. doi:10.1196/annals.1386.051.
Candore G, Colonna-Romano G, Balistreri CR, Di Carlo D, Grimaldi MP, Listì F, et al. Biology of longevity: role of the innate immune system. Rejuvenation Res. 2006;9:143–8. doi:10.1089/rej.2006.9.143.
Candore G, Balistreri CR, Colonna-Romano G, Grimaldi MP, Lio D, Listi' F, et al. Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res. 2008;11:425–32. doi:10.1089/rej.2008.0662.
Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev. 2005;205:257–68. doi:10.1111/j.0105-2896.2005.00271.
Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol. 2009;19:47–56. doi:10.1002/rmv.598.
Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435–46. doi:10.1111/j.1365-2567.2007.02555.x.
Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144–56. doi:10.1002/path.2104.
Troen BR. The biology of aging. Mt Sinai J Med. 2003;70:3–22.
Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, et al. IMUSCE. The extreme longevity: the state of the art in Italy. Exp Gerontol. 2008;43:45–52. doi:10.1016/j.exger.2007.06.006.
Capri M, Salvioli S, Monti D, Caruso C, Candore G, Vasto S, et al. Human longevity within an evolutionary perspective: the peculiar paradigm of a post-reproductive genetics. Exp Gerontol. 2008;43:53–60. doi:10.1016/j.exger.2007.06.004.
Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007;128:83–91. doi:10.1016/j.mad.2006.11.015.
Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 2004;39:687–99. doi:10.1016/j.exger.2004.01.009.
Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J Infect Chemother. 2008;14:86–92. doi:10.1007/s10156-008-0596-1.
Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227:75–86. doi:10.1111/j.1600-065X.2008.00737.x.
Uematsu S, Akira S. Toll-like receptors (TLRs) and their ligands. Handb Exp Pharmacol. 2008;183:1–20. doi:10.1007/978-3-540-72167-3_1.
Blander JM. Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors. Ann Rheum Dis. 2008;67(Suppl 3):iii44–9. doi:10.1136/ard.2008.097964.
Netea MG, van de Veerdonk FL, Kullberg BJ, Van der Meer JW, Joosten LA. The role of NLRs and TLRs in the activation of the inflammasome. Expert Opin Biol Ther. 2008;8:1867–72. doi:10.1517/14712590802494212.
Richards S, Watanabe C, Santos L, Craxton A, Clark EA. Regulation of B-cell entry into the cell cycle. Immunol Rev. 2008;224:183–200. doi:10.1111/j.1600-065X.2008.00652.x.
Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51. doi:10.1016/j.cyto.2008.01.006.
Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal–ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988;29(52):269–79.
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–7. doi:10.1038/41131.
Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004;76:514–9. doi:10.1189/jlb.0304127.
Zeytun A, van Velkinburgh JC, Pardington PE, Cary RR, Gupta G. Pathogen-specific innate immune response. Adv Exp Med Biol. 2007;598:342–57. doi:10.1007/978-0-387-71767-8_24.
Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007;19:3–10. doi:org/10.1016/j.smim.2006.12.002.
Ku C-L, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, et al. Inherited disorders of human Toll-like receptor signaling: Immunological implications. Immunol Rev. 2005;203:10–20. doi:10.1111/j.0105-2896.2005.00235.x.
Balistreri CR, Candore G, Colonna-Romano G, Grimaldi MP, Lio D, Listì F, et al. Role of TLR polymorphisms in immunosenescence. In: Fulop T, editor. Handbook on Immunosenescence. Netherlands: Springer; 2009. p. 659–70. doi:10.1007/978-1-4020-9062-2_1.
van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Soc. 2007;55:1438–44. doi:10.1111/j.1532-5415.2007.01300.x.
Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am. 2003;23:15–39. doi:10.1016/S0889-8561(02)00056-5.
Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev. 1998;102:199–209. doi:10.1016/S0047-6374(97)00153-X.
Fulop T, Larbi A, Douziech N, Fortin C, Guérard KP, Lesur O, et al. Signal transduction and functional changes in neutrophils with aging. Aging Cell. 2004;3:217–26. doi:10.1111/j.1474-9728.2004.00110.x.
van Duin D, Mohanty S, Thomas V, Ginter S, Montgomery RR, Fikrig E, et al. Age-associated defect in human TLR-1/2 function. J Immunol. 2007;178:970–5.
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54. doi:10.1111/j.1749-6632.2000.tb06651.x.
Agrawal A, Agrawal S, Gupta S. Dendritic cells in human aging. Exp Gerontol. 2007;42:421–6. doi:0.1007/s10875-007-9127-6.
Rea IM, Candore G, Cavalloni L, Franceschi C, Colonna-Romano G, Lio D, et al. Longevity. In: Vandenbroeck K, editor. Cytokine gene polymorphisms in multifactorial conditions. Florida: CRC; 2006. p. 379–94. ISBN 9780849336195.
van Duin D, Allore HG, Mohanty S, Ginter S, Newman FK, Belshe RB, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis. 2007;195:1590–7. doi:10.1086/516788.
Smirnova I, Poltorak A, Chan EK, McBride C, Beutler B. Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol. 2000;1(1):RESEARCH002.1–RESEARCH002.10.
Mushegian A, Medzhitov R. Evolutionary perspective on innate immune recognition. J Cell Biol. 2001;155:705–10. doi:10.1083/jcb.200107040.
Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A. 2007;104:16645–50. doi:10.1073/pnas.0704828104.
Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW, et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med. 2008;14:346–52. doi:10.2119/2007-00135.
Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–91. doi:10.1038/76048.
Balistreri CR, Candore G, Listì F, Fazio T, Gangi S, Incalcaterra E, et al. Role of TLR4 polymorphisms in inflammatory responses: implications for unsuccessful aging. Ann N Y Acad Sci. 2007;1119:203–7. doi:10.1196/annals.1404.003.
Vasto S, Candore G, Listì F, Balistreri CR, Colonna-Romano G, Malavolta M, et al. Inflammation, genes and zinc in Alzheimer's disease. Brain Res Brain Res Rev. 2008;58:96–105. doi:10.1016/j.brainresrev.2007.12.001.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421. doi:10.1016/S0197-4580(00)00124-X.
Streit WJ, Miller KR, Lopes KO, Njie E. Microglial degeneration in the aging brain—bad news for neurons? Front Biosci. 2008;13:3423–38. doi:10.2741/2937.
Fassbender K, Walter S, Kühl S, Landmann R, Ishii K, Bertsch T, et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 2004;18:203–5. doi:10.1096/fj.03-0364fje.
Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol. 2008;213:114–21. doi:10.1016/j.expneurol.2008.05.014.
Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol. 2002;61:1013–21.
Finch CE, Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res. 2007;4:185–9. doi:10.2174/156720507780362254.
Candore G, Balistreri CR, Grimaldi MP, Listì F, Vasto S, Chiappelli M, et al. Polymorphisms of pro-inflammatory genes and Alzheimer’s disease risk: a pharmacogenomic approach. Mech Ageing Dev. 2007;128:67–75. doi:10.1016/j.mad.2006.11.013.
Minoretti P, Gazzaruso C, Vito CD, Emanuele E, Bianchi M, Coen E, et al. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci Lett. 2006;391:147–9. doi:10.1016/j.neulet.2005.08.047.
Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L, Listì F, et al. Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Curr Pharm Des. 2008;14:2672–7. doi:10.2174/138161208786264089.
Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65:5009–14. doi:10.1158/0008-5472.CAN-05-0784.
Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859. doi:10.1158/0008-5472.CAN-05-3948.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–69. doi:10.1038/nrc2090.
Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, et al. Inflammation, ageing and cancer. Mech Ageing Dev. 2009;130:40–5. doi:10.1016/j.mad.2008.06.003.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96. doi:10.1016/j.cell.2004.07.013.
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59. doi:10.1038/nri1703.
van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology. 2008;124:445–52. doi:10.1111/j.1365-2567.2008.02871.x.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi:10.3322/CA.2007.0010.
Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;24(349):366–81.
Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54:1951–60. doi:10.1373/clinchem.2008.110668.
Caruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di Bon AD, et al. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009. doi:10.1007/s00262-009-0658-y.
Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. 2004;64:2918–22. doi:10.1158/0008-5472.CAN-03-3280.
Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005;65:11771–8. doi:10.1158/0008-5472.CAN-05-2078.
Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:352–5. doi:10.1158/1055-9965.EPI-06-0429.
Balistreri CR, Caruso C, Carruba G, Miceli V, Campisi I, Lio D, Colonna-Romano G. F. Listì F,Candore G. A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Des. 2009. (in press).
Vink A, de Kleijn DP, Pasterkamp G. Functional role for toll-like receptors in atherosclerosis and arterial remodeling. Curr Opin Lipidol. 2004;15:515–21. doi:10.1097/00041433-200410000-00004.
Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004;34:328–34. doi:10.1111/j.1365-2362.2004.01338.x.
Bjorkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol. 2006;17:527–33.
Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res. 2006;34:193–209. doi:10.1385/IR:34:3:193.
Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444–54. doi:10.1038/ncpcardio0938.
Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des. 2006;12:4229–45. doi:10.2174/138161206778743501.
Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185–92. doi:10.1056/NEJMoa012673.
Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest. 2004;34:94–9. doi:10.1111/j.1365-2362.2004.01303.x.
Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, et al. Effect of the Toll-like receptor 4 (TLR-4) variants on intima–media thickness and monocyte-derived macrophage response to LPS. J Intern Med. 2005;258:21–7. doi:10.1111/j.1365-2796.2005.01509.x.
Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS. Toll receptor polymorphisms and carotid artery intima–media thickness. Stroke. 2007;38:1179–84. doi:10.1161/01.STR.0000260184.85257.2b.
Hernesniemi JA, Raitakari OT, Kähönen M, Juonala M, Hutri-Kähönen N, Marniemi J, et al. Toll-like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity. The cardiovascular risk in young Finns study. Atherosclerosis. 2008;198:152–9. doi:10.1016/j.atherosclerosis.2007.09.024.
Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol. 2003;23:e61–4. doi:10.1161/01.ATV.0000101191.92392.1D.
Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, et al. REgression GRowth Evaluation Statin Study Group. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003;107:2416–21. doi:10.1161/01.CIR.0000068311.40161.28.
Yang IA, Holloway JW, Ye S. Southampton Atherosclerosis Study (SAS) Group. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis. 2003;170:187–90. doi:10.1016/S0021-9150(03)00286-7.
Edfeldt K, Bennet AM, Eriksson P, Frostegård J, Wiman B, Hamsten A, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J. 2004;25:1447–53. doi:10.1016/j.ehj.2004.05.004.
Morange PE, Tiret L, Saut N, Luc G, Arveiler D, Ferrieres J, et al. PRIME Study Group. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and therisk of coronary heart disease: the PRIME study. Eur J Hum Genet. 2004;12:1041–9. doi:10.1038/sj.ejhg.5201277.
Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics. 2005;15:15–21. doi:10.1097/01213011-200501000-00003.
Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke. 2005;36:154–7. doi:10.1161/01.STR.0000149948.31879.f0.
Koch W, Hoppmann P, Pfeufer A, Schömig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J. 2006;27:2524–9. doi:10.1093/eurheartj/ehl231.
Terry DF, Wilcox M, McCormick MA, Lawler E, Perls TT. Cardiovascular advantages among the offspring of centenarians. J Gerontol A Biol Sci Med Sci. 2003;58:M425–31.
Terry DF, Wilcox MA, McCormick MA, Pennington JY, Schoenhofen EA, Andersen SL, et al. Lower all-cause, cardiovascular, and cancer mortality in centenarians' offspring. Am Geriatr Soc. 2004;52:2074–6. doi:10.1111/j.1532-5415.2004.52561.x.
Lio D, Candore G, Crivello A, Scola L, Colonna-Romano G, Cavallone L, et al. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet. 2004;41:790–4. doi:10.1136/jmg.2004.019885.
Grimaldi MP, Candore G, Vasto S, Caruso M, Caimi G, Hoffmann E, et al. Role of the pyrin M694V (A2080G) allele in acute myocardial infarction and longevity: a study in the Sicilian population. J Leukoc Biol. 2006;79:611–5. doi:10.1189/jlb.0705416.
Listì F, Candore G, Balistreri CR, Caruso M, Incalcaterra E, Hoffmann E, et al. Connexin37 1019 gene polymorphism in myocardial infarction patients and centenarians. Atherosclerosis. 2007;191:460–1. doi:10.1016/j.atherosclerosis.2006.08.009.
Listì F, Candore G, Grimaldi MP, Lio D, Colonna-Romano G, Orlando V, et al. Alpha1-antitrypsin heterozygosity plays a positive role in attainment of longevity. Biogerontology. 2007;8:139–45. doi:10.1007/s10522-006-9041-y.
Nuzzo D, Vasto S, Balistreri CR, Di-Carlo D, Listì F, Caimi G, et al. Role of proinflammatory alleles in longevity and atherosclerosis: results of studies performed on -1562C/T MMP-9 in centenarians and myocardial infarction patients from Sicily. Ann N Y Acad Sci. 2006;1089:496–501. doi:10.1196/annals.1386.048.
Listì F, Caruso C, Balistreri CR, Grimaldi MP, Caruso M, Caimi G, et al. PECAM-1/CD31 in infarction and longevity. Ann N Y Acad Sci. 2007;1100:132–9. doi:10.1196/annals.1395.011.
Balistreri CR, Candore G, Caruso M, Incalcaterra E, Franceschi C, Caruso C. Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica. 2008;93:637–8. doi:10.3324/haematol.12239.
Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, et al. Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des. 2008;14:2678–85. doi:10.2174/138161208786264115.
Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA. 2004;292:2339–40. doi:10.1001/jama.292.19.2339.
Nebel A, Flachsbart F, Schäfer A, Nothnagel M, Nikolaus S, Mokhtari NE, et al. Role of the toll-like receptor 4 polymorphism Asp299Gly in longevity and myocardial infarction in German men. Mech Ageing Dev. 2007;128:409–11. doi:10.1016/j.mad.2007.04.001.
Barzi F, Woodward M, Marfisi RM, Tavazzi L, Valagussa F, Marchioli R. GISSI-Prevenzione Investigators. Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial. Eur J Clin Nutr. 2003;57:604–11. doi:10.1038/sj.ejcn.1601575.
Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, et al. Caruso C. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2:8. doi:10.1186/1742-4933-2-8.
Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5:156–64. doi:10.1016/S1473-3099(05)01308-3.
Acknowledgments
This work was supported by the Italian Ministry of Health grant (molecular mechanisms of stem cancer cell survival control) to C. Caruso and by the Ministry of Education, University and Research (ex60%) grant to G. Candore and C. Caruso.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balistreri, C.R., Colonna-Romano, G., Lio, D. et al. TLR4 Polymorphisms and Ageing: Implications for the Pathophysiology of Age-Related Diseases. J Clin Immunol 29, 406–415 (2009). https://doi.org/10.1007/s10875-009-9297-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-009-9297-5